Recycling tenofovir after failure of first-line treatment vs switching to second-line zidovudine is associated with better care retention, adherence, and viral load suppression in HIV patients, especially when combined with atazanavir boosted with ritonavir, a new study presented at AIDS 2020 Virtual has shown.
HIV-1 RNA viral suppression is comparable between tenofovir alafenamide (TAF)/emtricitabine (FTC) + dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC + DTG, and TDF/FTC/efavirenz (EFV) regimens, according to updated results of the ADVANCE trial.
A dolutegravir-based regimen continued to show noninferiority to a low-dose efavirenz-based regimen after 96 weeks for the initial treatment of HIV-1 infection, according to the updated results of the NAMSAL* trial presented at AIDS 2020.
The once-daily single-tablet combination therapy comprising darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) yields high virologic response rates over 96 weeks in patients with HIV-1, regardless of the presence of neurologic and/or psychiatric comorbidities (NPCs), a subgroup analysis presented at the AIDS 2020 virtual conference has shown.
The concomitant use of depot medroxyprogesterone acetate (DMPA) in young women with HIV initiating an antiretroviral therapy (ART) regimen containing tenofovir disoproxil fumarate (TDF) may lead to worsening of bone mineral density (BMD) loss, data presented at AIDS 2020 have shown.
Rapid treatment initiation with a single-tablet regimen comprising darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) demonstrated a high virological response rate in patients with acute or early HIV-1* infection, according to a subgroup analysis of the DIAMOND** study presented at AIDS 2020.
Switching to a single-tablet triple-drug combination comprising bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is well tolerated while continuing to provide virologic suppression through to 48 weeks in elderly people (aged ≥65 years) living with HIV (PLWH), shows a pooled analysis presented at the AIDS 2020 virtual conference.
Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Treatment with intravenous (IV) dexamethasone for 10 days significantly reduces duration of mechanical ventilation at 28 days and 60-day mortality in patients with established moderate-to-severe acute respiratory disease syndrome (ARDS) compared with no dexamethasone, results of the DEXA-ARDS trial have shown.